Rock Ventures Ii, L.P.Third... Net Worth

The estimated Net Worth of Rock Ventures Ii, L.P.Third... is at least $113 Milion dollars as of 25 September 2017. Rock Third owns over 601,400 units of Sage Therapeutics Inc stock worth over $51,569,429 and over the last 10 years Rock sold SAGE stock worth over $61,560,325.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Rock Third SAGE stock SEC Form 4 insiders trading

Rock has made over 3 trades of the Sage Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Rock sold 601,400 units of SAGE stock worth $25,860,200 on 25 September 2017.

The largest trade Rock's ever made was selling 850,000 units of Sage Therapeutics Inc stock on 16 May 2016 worth over $26,562,500. On average, Rock trades about 104,541 units every 31 days since 2015. As of 25 September 2017 Rock still owns at least 6,885,104 units of Sage Therapeutics Inc stock.

You can see the complete history of Rock Third stock trades at the bottom of the page.

What's Rock Third's mailing address?

Rock's mailing address filed with the SEC is Newbury St, Boston, MA, USA.

Insiders trading at Sage Therapeutics Inc

Over the last 10 years, insiders at Sage Therapeutics Inc have traded over $190,046,458 worth of Sage Therapeutics Inc stock and bought 150,092 units worth $6,260,297 . The most active insiders traders include Kevin P Starr, Robert Nelsen oraz Michael F Cola. On average, Sage Therapeutics Inc executives and independent directors trade stock every 32 days with the average trade being worth of $256,667. The most recent stock trade was executed by Kimi Iguchi on 2 January 2024, trading 1,642 units of SAGE stock currently worth $2,233.

What does Sage Therapeutics Inc do?

sage therapeutics is a neuroscience-focused company developing medicines to treat life-threatening, rare cns disorders. our mission is to make life better for patients with central nervous systems diseases by discovering, developing, and delivering important new medicines to the market. to achieve that mission we leverage compelling science, a robust clinical foundation, strong partnerships, and a world-class team of founders, advisors, investors, scientists and managers. sage’s lead program, sage-547, is in clinical development for super-refractory status epilepticus (srse) and is the first of many compounds the company is developing in its portfolio of potential seizure medicines. sage’s robust chemistry platform has generated multiple new compounds that target the gabaa and nmda receptors, which have demonstrated preclinical activity. sage therapeutics is a private company launched in 2010 by an experienced team of r&d leaders, cns experts and investors.

Complete history of Rock Third stock trades at Global Blood Therapeutics, MyoKardia oraz Sage Therapeutics Inc

Sage Therapeutics Inc executives and stock owners

Sage Therapeutics Inc executives and other stock owners filed with the SEC include:

• Jeffrey Jonas,
  President, Chief Executive Officer and Director
• Michael Cloonan,
  Chief Operating Officer
• Stephen Kanes,
  Chief Medical Officer
• Anne Cook,
  Senior Vice President, General Counsel, Secretary
• Kimi Iguchi,
  Chief Financial Officer, Treasurer
• Albert Robichaud,
  Chief Scientific Officer
• Elizabeth Barrett,
  Independent Director
• George Golumbeski,
  Independent Director
• Dr. Jeffrey M. Jonas,
  Chief Innovation Officer, Chair of the Science & Technology Forum and Director
• Kevin Starr,
  Independent Chairman of the Board
• Michael Cola,
  Independent Director
• James Frates,
  Independent Director
• Steven Paul,
  Independent Director
• Geno Germano,
  Independent Director
• Asha Nayak,
  Independent Director
• Anne Marie Cook,
  Sr. VP, Gen. Counsel & Sec.
• Dr. Albert J. Robichaud Ph.D.,
  Chief Scientific Officer
• Kimi E. Iguchi,
  CFO & Treasurer
• Barry E. Greene,
  Pres, CEO & Director
• Barry Greene,
  Director
• Dr. Jim Doherty Ph.D.,
  Chief Devel. Officer
• Dr. Amy Schacterle Ph.D.,
  Sr. VP of R&D Strategy and Bus. Management
• Erin E. Lanciani,
  Chief People & Experience Officer
• Helen Rubinstein,
  Investor Relations Officer
• Matt Lasmanis,
  Chief Technology & Innovation Officer
• Rock Ventures Ii, L.P.Third...,
  
• Howard H Pien,
  
• Thomas Anderson,
  See Remarks
• Robert Nelsen,
  Director
• Venture Fund Vii Lparch Ven...,
  
• Rock Ventures Ii, L.P.Third...,
  
• Laura Gault,
  Chief Medical Officer
• Jessica Federer,
  
• Christopher Benecchi,
  Chief Business Officer